Cargando…

Incorrect description of mode of excretion of linagliptin

Detalles Bibliográficos
Autores principales:	Woerle, Hans-Juergen, Patel, Sanjay
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2010
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3108713/ https://www.ncbi.nlm.nih.gov/pubmed/21701621

Ejemplares similares

Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme
por: Johansen, Odd Erik, et al.
Publicado: (2012)

Incorrect predictions, not incorrect statistics!
por: Hoff, Reinier G, et al.
Publicado: (2009)

Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events
por: Rosenstock, Julio, et al.
Publicado: (2015)

Effects of Adding Linagliptin to Basal Insulin Regimen for Inadequately Controlled Type 2 Diabetes: A ≥52-week randomized, double-blind study
por: Yki-Järvinen, Hannele, et al.
Publicado: (2013)

Efficacy and safety of linagliptin monotherapy in Asian patients with inadequately controlled type 2 diabetes mellitus: A multinational, 24-week, randomized, clinical trial
por: Chen, Yuhong, et al.
Publicado: (2015)

Long-Term Efficacy and Safety of Linagliptin in Patients With Type 2 Diabetes and Severe Renal Impairment: A 1-year, randomized, double-blind, placebo-controlled study
por: McGill, Janet B., et al.
Publicado: (2013)

Incorrect Descriptive Statistical Data
Publicado: (2019)

Linagliptin Lowers Albuminuria on Top of Recommended Standard Treatment in Patients With Type 2 Diabetes and Renal Dysfunction
por: Groop, Per-Henrik, et al.
Publicado: (2013)

Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: a pooled analysis of six phase III clinical trials
por: von Eynatten, Maximilian, et al.
Publicado: (2013)

Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA(®))
por: Marx, Nikolaus, et al.
Publicado: (2015)

Influence of TCF7L2 gene variants on the therapeutic response to the dipeptidylpeptidase-4 inhibitor linagliptin
por: Zimdahl, Heike, et al.
Publicado: (2014)

Linagliptin Increases Incretin Levels, Lowers Glucagon, and Improves Glycemic Control in Type 2 Diabetes Mellitus
por: Rauch, Thomas, et al.
Publicado: (2012)

Efficacy and safety of linagliptin in Hispanic/Latino patients with type 2 diabetes mellitus: a pooled analysis from six randomized placebo-controlled phase 3 trials
por: Davidson, Jaime A, et al.
Publicado: (2014)

Incorrect use of meta-analytic procedures
por: Shatadal, Pooja, et al.
Publicado: (2023)

Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment
por: Groop, P-H, et al.
Publicado: (2014)

Incorrect Equations
Publicado: (2014)

An Incorrect Statement
por: Gorgas, Ferdinand J. S.
Publicado: (1889)

Incorrect Affiliation
Publicado: (2019)

Incorrect Address
Publicado: (2022)

An incident of incorrect blood component transfusion: The need for constant hemovigilance
por: Malhotra, Sheetal, et al.
Publicado: (2015)

The homeoviscous adaptation to dietary lipids (HADL) hypothesis is probably incorrect
por: Christensen, Jacob J, et al.
Publicado: (2021)

Initial combination of linagliptin and metformin in patients with type 2 diabetes: efficacy and safety in a randomised, double-blind 1-year extension study
por: Haak, T, et al.
Publicado: (2013)

Incorrect Wording in Results
Publicado: (2019)

Population Pharmacokinetics and Pharmacodynamics of Linagliptin in Patients with Type 2 Diabetes Mellitus
por: Retlich, Silke, et al.
Publicado: (2015)

Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with Type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone: a 24-week randomized, double-blind study
por: Bajaj, M, et al.
Publicado: (2014)

Sampling bias and incorrect rooting make phylogenetic network tracing of SARS-COV-2 infections unreliable
por: Mavian, Carla, et al.
Publicado: (2020)

Community Pharmacists Do Not Intentionally Transmit Incorrect Claim Information - But Caution Is Warranted in Days Supply Calculations
por: Gans, John
Publicado: (2004)

The clinical application of linagliptin in Asians
por: Cao, Chu-qing, et al.
Publicado: (2015)

Linagliptin: from bench to bedside
por: Doupis, John
Publicado: (2014)

Erratum: Incorrect Volume Number
Publicado: (2013)

Incorrect Reporting of Statistical Tests
Publicado: (2020)

Incorrect Date in the Methods Section
Publicado: (2020)

Incorrect Trial Registration Identifier
Publicado: (2022)

Incorrect Data in Results and Figures
Publicado: (2023)

Incorrect Date in Figure 1
Publicado: (2023)

Female Sex Workers Often Incorrectly Interpret HIV Self-Test Results in Uganda
por: Ortblad, Katrina F., et al.
Publicado: (2018)

Authors’ response: importance of a careful investigation to avoid attributing Legionnaires’ disease cases to an incorrect source of infection
por: Palazzolo, Claudia, et al.
Publicado: (2020)

Letter to the editor: importance of a careful investigation to avoid attributing Legionnaires’ disease cases to an incorrect source of infection
por: Rota, Maria Cristina, et al.
Publicado: (2020)

Rumors and incorrect reports are more deadly than the new coronavirus (SARS-CoV-2)
por: Jalali, Rostam, et al.
Publicado: (2020)

Acute Kidney Injury Associated with Linagliptin
por: Nandikanti, Deepak K., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_9sf99i8b5db097me7v8mhoidff